



December 17, 2024

PeptiDream Inc
<https://www.peptidream.com>
(Securities Code: 4587 TSE Prime Market)
PDRadiopharma Inc
<https://www.pdradiopharma.com>

PeptiDream to Construct New Radiotherapeutic/Radiodiagnostic Manufacturing Facility at Kazusa Akademia Park, Chiba

KANAGAWA, JAPAN – December 17, 2024 – PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) today announced its plans to construct a new state-of-the-art manufacturing facility at Kazusa Akademia Park in Chiba, Japan, for the clinical supply and commercial production of the company’s next generation targeted radiopharmaceuticals (*utilizing the radionuclides Lu-177, Ac-225, Cu-64, etc., *1*), with PeptiDream’s Masato Murakami (President of PDRadiopharma and CMO at PeptiDream) formally submitting the company’s application to move into Kazusa Akademia Park to the Chiba Prefectural Government.

PeptiDream is a global leader in the discovery and development of peptide-based therapeutics utilizing its proprietary PDPS (Peptide Discovery Platform System) technology, including a growing pipeline of wholly-owned and partnered next-generation peptide-radioisotope (peptide-RI) conjugates for use as targeted radiotherapeutics and radiodiagnostic agents. PDRadiopharma, a wholly-owned subsidiary of PeptiDream, develops, manufactures, and sells a broad range of radiodiagnostic and radiotherapeutic products in Japan, and as the leading radiopharmaceutical company in Japan, is focused on not only bringing PeptiDream’s peptide-RI conjugate programs (*GPC3 program, CA9 program, Claudin18.2 program, etc.,*) to the Japan market, but also utilizing its extensive infrastructure and expertise to bring strategic partners (*Lilly, LinqMed, Curium, etc.,*) exciting radiopharmaceutical products to Japanese patients.

Currently, PDRadiopharma operates its main manufacturing site in Chiba (*Sanmu City*), with PET labs in Kanagawa (*Kawasaki City*) and Osaka (*Ibaraki City*). The new to-be-built manufacturing facility will sit on a 14-acre (57,000m²) site within Kazusa Akademia Park, an industrial park located in central Chiba (*~45min drive west to PeptiDream/Kanagawa PET lab/ Haneda Airport and ~1hr drive north to Chiba Sanmu site/Narita Airport*) and will focus on manufacturing the Group’s growing pipeline of targeted radiotherapeutic and theranostic product offerings (*2). Additionally, its proximal location to both Haneda and Narita Airports, will allow the Group to potentially export products out of Japan to other markets within the Asia-Pacific region as the radiopharmaceutical field continues to grow. Construction of the new facility is scheduled to start in 2026 and become fully operational in 2028. The project is expected to cost approximately 10 billion JPY and will be completely funded by cash on hand.

“As the leading radiopharmaceutical company in Japan, PeptiDream and PDRadiopharma are strategically focused on both discovering and developing a broad pipeline of next generation targeted radiotherapeutics and radiodiagnostics. Our

development pipeline, composed of both PeptiDream discovered programs (such as our wholly-owned CA9 program for kidney cancer and our partnered GPC3 program for liver cancer to which we retain Japan rights) along with PDRadiopharma strategic partnered programs (such as our LinqMed partnered ATSM program and our recent Curium partnered PSMA I&T programs) has shown significant growth over the past 12 months, a trend we very much expect to continue, necessitating additional manufacturing capacity to deliver these promising radiopharmaceuticals to patients both in Japan and overseas.” said **Patrick C. Reid, CEO of PeptiDream.**

“Kazusa Akademia Park is a large research and industrial park spanning parts of the cities of Kimitsu and Kisarazu in the central region of Chiba Prefecture and we believe this is an excellent choice for expanding PDRadiopharma’s manufacturing capacity. The new site is less than an hour drive west to PeptiDream’s Headquarters and PDRadiopharma’s PET site in Kawasaki, and just over an hour drive north to PDRadiopharma’s main manufacturing site in Sanmu, Chiba. In addition, it sits largely equal distance from both Haneda and Narita Airports, the two major metropolitan airports serving Tokyo, making it an ideal location for supplying our radiopharmaceutical products both across all of Japan as well as potentially the greater Asia-Pacific area.” said **Masato Murakami, President of PDRadiopharma and CMO of PeptiDream.**

【Overview of New Manufacturing Site】

Location	Kazusa Akademia Park, Chiba, Japan
Land Size	57,000 m ² (~14 acres)
Purpose	Development and Manufacture of both clinical and commercial supply of our next-generation radiopharmaceuticals
Products	Radiotherapeutics and radiodiagnostics containing Lu-177, Ac-225, Cu-64 etc.
Planning & Construction Schedule	Planning start: Spring 2025 Anticipated construction start: Summer 2026 Anticipated completion: Fall of 2028

*1 Next-generation radionuclides: In addition to the nuclides currently used in radiopharmaceuticals, we are promoting the development of new radiopharmaceuticals using next-generation radionuclides such as Ac-225 (an alpha-emitting nuclide that is expected to have a higher killing effect on cancer cells than beta-emitting nuclide) and Cu-64 (a nuclide used in PET diagnostic drugs, etc., with a longer half-life of approximately 13 hours compared to conventional F-18 (half-life of approximately 2 hours) allowing for a single manufacturing site to be able to supply a greater delivery area (e.g. all of Japan from one central site).

*2 Theranostics: A medical approach that integrates both treatment and diagnosis by using different nuclides for diagnosis and treatment based on the same targeting molecule, such as peptides. Theranostics makes it possible to perform cancer diagnosis and treatment in an integrated manner and is expected to have benefits such as effectively selecting patients who are most likely to benefit from treatment and being able to monitor the effectiveness of treatment at any time.

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and

sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our PeptiDream, science and pipeline, please visit www.peptidream.com.

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Public Affairs

Email: info@peptidream.com